Having trouble accessing articles? Reset your cache.

FDA proposes comparative approval standards for new opioids

FDA is moving to establish comparative effectiveness standards for approval of new opioids, according to draft guidance issued Thursday on conducting benefit-risk assessments.

Former FDA Commissioner Scott Gottlieb proposed such a standard shortly before he left the position.

Read the full 371 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers